Skip to main content

Table 5 Criteria for S-1 skipping and reduction of docetaxel and S-1 from the next course in the postoperative DS chemotherapy

From: Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study

  S-1 skipping Docetaxel and S-1 reduction from the next course
Neutrophil count decreased Grade 3 Grade 4
Platelet count decreased Grade 3 Grade 3
Creatinine increased >1.5 mg/dL >1.5 mg/dL
Febrile neutropenia Grade 3
Infection Grade 3
Diarrhea, Oral mucositis, Rash Grade 2 Grade 3
Nausea, Fatigue Grade 2 Grade 3
Vomiting, Anorexia Grade 2 Grade 3
Infusion reaction Grade 2
Hypernatremia, Hyponatremia, Hyperkalemia, Hypokalemia Grade 2 Grade 3
  1. DS docetaxel and S-1. Grades are written according to Common Terminology Criteria for Adverse Events (CTCAE) Version5.0